Lancet Gastroenterology & Hepatology最新文献

{"title":"Vedolizumab for prevention of recurrence of Crohn's disease","authors":"Nassim Hammoudi, Matthieu Allez","doi":"10.1016/s2468-1253(24)00430-8","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00430-8","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"13 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research in Brief","authors":"Holly Baker","doi":"10.1016/s2468-1253(25)00021-4","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00021-4","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>TACE and immunotherapies for hepatocellular carcinoma</h2>Two phase 3 trials—EMERALD-1 and LEAP-012—highlight promising advances in the treatment of unresectable hepatocellular carcinoma with transarterial chemoembolisation (TACE) combined with immunotherapeutic agents.In EMERALD-1, Bruno Sangro and colleagues randomly assigned patients with unresectable hepatocellular carcinoma amenable to embolisation to receive TACE (current standard of care) plus either durvalumab plus bevacizumab (n=204), durvalumab plus placebo (n=207), or placebo alone (n=205).</section></section><section><section><h2>Thermal ablation for small colorectal liver metastases</h2>Thermal ablation is as efficacious as surgical resection for treating small colorectal liver metastases, but with fewer complications, according to the COLLISION phase 3 trial.Susan van der Lei and colleagues randomly assigned patients with ten or fewer small-size (≤3 cm) colorectal liver metastases to receive either thermal ablation (n=148) or surgical resection (n=148). The study was stopped early at a preplanned interim analysis, after a median follow-up of 28·9 months, based on a</section></section><section><section><h2>Perioperative chemotherapy for oesophageal cancer</h2>Perioperative chemotherapy improves survival in patients with resectable oesophageal adenocarcinoma, according to the ESOPEC phase 3 trial.Jens Hoeppner and colleagues randomly assigned patients to receive either perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery (n=221) or preoperative chemoradiotherapy (radiotherapy at 41·4 Gy and carboplatin and paclitaxel) plus surgery (n=217). At median follow-up of 55 months, 3-year overall survival</section></section><section><section><h2>Plozasiran for persistent chylomicronaemia</h2>The siRNA plozasiran significantly lowers triglyceride levels and reduces the risk of pancreatitis in patients with persistent chylomicronaemia, suggests the PALISADE phase 3 trial.Gerald F Watts and colleagues randomly assigned patients to receive plozasiran at 25 mg (n=26) or 50 mg (n=24), or placebo (n=25), subcutaneously every 3 months for 12 months. At 10 months, the median percentage change from baseline in fasting triglyceride level was −80% in the plozasiran 25 mg group, −78% in the</section></section>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"2 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking the silence: MASLD and the scarcity of data on the Roma population","authors":"Paula Iruzubieta, Javier Crespo","doi":"10.1016/s2468-1253(25)00019-6","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00019-6","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"55 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143385127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming the challenges of overtreating and undertreating inflammatory bowel disease","authors":"Maria José Temido, Sailish Honap, Vipul Jairath, Severine Vermeire, Silvio Danese, Francisco Portela, Laurent Peyrin-Biroulet","doi":"10.1016/s2468-1253(24)00355-8","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00355-8","url":null,"abstract":"Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding therapeutic armamentarium and the increasingly ambitious treatment targets have led to an increased use of advanced therapies and better outcomes. Nevertheless, many patients remain suboptimally treated and are at risk of disease progression, hospital admission, and surgery, even when advanced therapies are cycled, escalated, or combined. Conversely, IBD can also be characterised by an indolent disease course. Top-down and treat-to-target strategies, although beneficial in a substantial proportion of patients, might not be advantageous in patients with mild disease and might risk overtreatment. Identifying patients with mild activity and a benign disease trajectory in the long-term is important; unnecessary exposure to advanced therapies increases the risk of adverse events and increases financial costs and health-care resource utilisation. This Review details the importance of adopting clinical strategies to avoid the pitfalls of undertreating and overtreating IBD.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"61 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143192050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogens don't respect politicians: US federal disruption poses a new threat to global public health","authors":"Su Wang, Mark Harrington, Camilla S Graham, Louise O Downs, Nancy Kagwanja, Anthony O Etyang, Collins Iwuji, Thumbi Ndung'u, Benjamin C Cowie, Kenneth Kabagambe, Philippa C Matthews","doi":"10.1016/s2468-1253(25)00045-7","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00045-7","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"55 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143258068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial","authors":"Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, Chi-Yi Chen, Won-Mook Choi, Wonseok Kang, Gi-Ae Kim, Hyung Joon Kim, Yun Bin Lee, Jeong-Hoon Lee, Neung Hwa Park, So Young Kwon, Soo Young Park, Ji Hoon Kim, Gwang Hyeon Choi, Eun Sun Jang, Chien-Hung Chen, Yao-Chun Hsu, Ming-Jong Bair, Pin-Nan Cheng, Seungbong Han","doi":"10.1016/s2468-1253(24)00431-x","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00431-x","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Current guidelines for chronic hepatitis B recommend antiviral therapy for individuals with non-cirrhotic chronic hepatitis B only if they have significant liver fibrosis or elevated alanine aminotransferase (ALT) concentrations. We aimed to assess the efficacy of early antiviral treatment in preventing serious liver-related adverse events in individuals with non-cirrhotic chronic hepatitis B and moderate or high viraemia but normal or mildly elevated ALT concentrations.&lt;h3&gt;Methods&lt;/h3&gt;ATTENTION is an ongoing randomised controlled trial being conducted at 22 centres in South Korea and Taiwan. Adults aged 40–80 years with non-cirrhotic chronic hepatitis B and serum hepatitis B virus (HBV) DNA concentrations between 4 log&lt;sub&gt;10&lt;/sub&gt; IU/mL and 8 log&lt;sub&gt;10&lt;/sub&gt; IU/mL, and ALT concentrations lower than 70 U/L for males and 50 U/L for females were recruited and randomly assigned (1:1) to receive either oral tenofovir alafenamide (25 mg daily) or no antiviral treatment (observation). The primary endpoint was a composite of hepatocellular carcinoma, hepatic decompensation (eg, development of portal hypertensive complications including ascites, gastro-oesophageal varices, or Child-Pugh score of ≥7), liver transplantation, or death from any cause, analysed in the intention-to-treat population. The safety population comprised all randomly assigned participants who received at least one dose of the study treatment. This interim analysis was prespecified at 4 years after enrolment of the first participant. This study is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT03753074&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;.&lt;h3&gt;Findings&lt;/h3&gt;Between Feb 8, 2019 and Oct 17, 2023 (the cutoff date for the first interim analysis), 798 individuals were screened and 734 were randomly assigned (369 to tenofovir alafenamide and 365 to observation). At a median follow-up of 17·7 months (IQR 8·3–24·4), the primary endpoint occurred in 11 participants: two in the tenofovir alafenamide group (both hepatocellular carcinoma) and nine in the observation group (seven hepatocellular carcinoma, one hepatic decompensation, and one death), corresponding to an incidence rate of 0·33 per 100 person-years in the tenofovir alafenamide group and 1·57 per 100 person-years in the observation group (hazard ratio 0·21 [97·5% CI 0·04–1·20]; p=0·027). The difference between the two groups did not surpass the prespecified boundaries required to stop the trial early. Serious adverse events, excluding primary endpoints, were reported in 23 (6%) participants in the tenofovir alafenamide gr","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"133 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143084083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applying the estimand framework to inflammatory bowel disease clinical trials","authors":"Nurulamin M Noor, Maria Manuela Estevinho, Virginia Solitano, Yuhong Yuan, Brennan C Kahan, Vipul Jairath","doi":"10.1016/s2468-1253(25)00004-4","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00004-4","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"34 4 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143084079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B","authors":"Asgeir Johannessen","doi":"10.1016/s2468-1253(25)00008-1","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00008-1","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"24 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143083769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD","authors":"Aleksander Krag, Nikolaj Torp, Zobair M Younossi, Mads Israelsen","doi":"10.1016/s2468-1253(24)00427-8","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00427-8","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"105 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142992104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotics versus appendicectomy in acute appendicitis: delay is not denial","authors":"Adewale O Adisa","doi":"10.1016/s2468-1253(24)00391-1","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00391-1","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"49 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142987954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}